Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annovis Bio, Inc. Common Stock (NY:ANVS)

2.100 +0.020 (+0.96%)
Official Closing Price Updated: 7:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Annovis Bio, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces $3.4 Million Registered Direct Offering
Via Investor Brand Network
Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Closes $6 Million Registered Direct Offering
Via Investor Brand Network
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
From Annovis Bio Inc.
Via GlobeNewswire
Annovis Announces $6 Million Registered Direct Offering of Common Stock
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports Biomarker Data Showing Buntanetap Reduces Inflammation and Strengthens Neuronal Health in Alzheimer’s Patients
Via Investor Brand Network
Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Appoints Mark Guerin as Chief Financial Officer
Via Investor Brand Network
Annovis Appoints Mark Guerin as Chief Financial Officer
From Annovis Bio Inc.
Via GlobeNewswire
Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present at H.C. Wainwright Global Investment Conference
Via Investor Brand Network
Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Advances Phase 3 Alzheimer’s Trial, Strengthens IP Portfolio, Reports Q2 2025 Results
Via Investor Brand Network
Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Secures Full Patent Coverage for New Crystalline Form of Buntanetap
Via Investor Brand Network
Topics Intellectual Property
Annovis Completes Full Patent Transfer to Crystal Buntanetap
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Present Alzheimer’s Advances at AAIC 2025 in Toronto
Via Investor Brand Network
Annovis to Attend the AAIC 2025 with Four Poster Presentations
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Gains 18-Month NYSE Compliance Window
Via Investor Brand Network
Topics Regulatory Compliance
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Host Webcast With CEO to Share Updates on Alzheimer’s and Parkinson’s Programs
Via Investor Brand Network
Annovis to Host Webinar and Live Q&A on June 24, 2025
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Advances Phase 3 Alzheimer’s Trial and Expands Conference Presence in Q1
Via Investor Brand Network
Topics Intellectual Property
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Appoints Hui Liu as Director of Biostatistics
Via Investor Brand Network
Annovis Bio Appoints Hui Liu as Director of Biostatistics
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives NYSE Noncompliance Notice Over Market Cap and Equity Levels
Via Investor Brand Network
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Present Late-Stage Alzheimer’s and Parkinson’s Data at AD/PD 2025
Via Investor Brand Network
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
From Annovis Bio Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.